| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab |
| 29 Oct 2026 |
8-K: Regulation FD Disclosure
Presentation and Q&A session scheduled for post-market on Thursday, November 5, 2026 |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
Presentation and Q&A session scheduled for post-market on Wednesday, August 5, 2026 |
| 12 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Ginkgo Bioworks Holdings, Inc. (the “Company”) held its 2026 annual meeting of shareholders (the “Annual Meeting”). A total of 39,536,848 shares of Class A common stock and 8,405,525 shares of Class B common stock were ... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab |
| 07 Apr 2026 |
8-K: Completion of Acquisition or Disposition of Assets
On April 3, 2026, Ginkgo Bioworks, Inc. (the “Seller”), a wholly owned subsidiary of Ginkgo Bioworks Holdings, Inc. (the “Company”), completed a transaction with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. (the “Purchas... |
| 27 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
Section 6.06 Return of Assets; Transfer of Business Assets 46 |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business |
| 23 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On December 18, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) announced that Dr. Reshma Shetty, the Company’s President, Chief Operating Officer, and member of the Board of Directors, will transition her Chief Operating Officer du... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Ginkgo provides an update on its third quarter financial results |
| 04 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
Ginkgo Bioworks Holdings, Inc.Shares of Class A Common Stock |
| 29 Aug 2025 |
8-K: Other Events
On May 27, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) entered into a Stipulation and Agreement of Settlement (the “Stipulation of Settlement”) to resolve certain stockholder derivative actions commenced nominally on behalf of t... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, Ginkgo Bioworks Holdings, Inc. (the “Company”) held its 2025 annual meeting of shareholders (the “Annual Meeting”). A total of 34,795,259 shares of Class A common stock and 8,371,744 shares of Class B common stock were ... |
| 21 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BOSTON, Mass. May 21, 2025 – Ginkgo Bioworks (NYSE: DNA, “Ginkgo” or the “Company”), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company’s Chief Financial Officer, i... |
| 06 May 2025 |
8-K: Results of Operations and Financial Condition
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target |
| 25 Feb 2025 |
8-K: Results of Operations and Financial Condition
Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions |
| 04 Sep 2024 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Other Events
On September 3, 2024, the New York Stock Exchange (the “NYSE”) notified Ginkgo Bioworks Holdings, Inc. (the “Company”), and, on September 4, 2024, publicly announced, that the NYSE has determined to (a) commence proceedings to delist the... |
Loading...